Article Text

PDF
GW24-e1133 Effect of Yindan Xinnaotong capsule on serum IL-6 of patients suffering from unstable angina pectoris
  1. Fei Hongbo,
  2. Ren Yanfeng,
  3. Fei Yu
  1. Cardiovascular Internal Medicine Department in Bethune Second Hospital of Jilin University

Abstract

Objectives Unstable angina pectoris (UAP) is a kind of common clinical type of coronary artery atherosclerosis heart disease. Due to the serious condition and great harm, the heart disease severely affects the physical and mental heath of people. It is believed that currently, pathomechanism of UAP is that, on the basis of the form of coronary artery atherosclerosis fracture, various plaque fracture elements lead to the fracture rupture, thus causing secondary thrombus, endothelium dysfunction and coronary artery spasm, which reduce the momentary blood flow in coronary artery and finally lead to the myocardial ischaemia. It is reported in some literature that interleukin-6 (IL-6) is closely related to the stability of the plaque and risk stratification of UAP. It is also reported in some literature that inflammatory cell and inflammatory factor react fiercest in the whole process of pathological changes and development of coronary artery atherosclerosis plaque. Plaque can be stabilised by controlling inflammation to prevent UAP. Yindan Xinnaotong Capsule is made of folium ginkgo, savia miltiorrhiza, erigeron breviscapus, panax pseudoginseng, hawthorn, gynostemma pentaphylla, garlic and natural ice, which has the functions such as promoting blood circulation to remove blood stasis, promoting the circulation of Qi and relieving the pains and promoting digestion to eliminate stagnation. It is reported in the literature that Yindan Xinnaotong Capsule can better cure UAP patients, but the functioning mechanism of the capsule is not very clear. Level of serum IL-6 of UAP patients is tested and Yindan Xinnaotong Capsule is used to intervene in order to explore the mechanism of curing UAP with Yindan Xinnaotong.

Methods 60 UAP patients are randomly divided into two groups (Incorporating standards are in accordance with diagnosis and treatment guidelines of UAP in Chinese Medical Association). 30 people are in the treatment group, and 30 are in control group. The two groups are all given the conventional therapy such as coronary dilatation (Isosorbide), anti-freezing and antiplatelet treatment (aspirin, low molecular heparin, clopidogrel), lipid regulation (atovastatin), inhibitor for angiotensin turning enzyme and b receptor blocker. People in the treatment group are given 2 pellets of Yindan Xinnaotong Capsule each time on the basis of above treatment. The capsule is taken orally three times a day with a course of treatment of three months. Venous blood is collected with empty stomach before and after treatment, which is centrifugal cryopreserved. Double-antibody sandwich ABC-ELISA test method is used to test the level of IL-6.

Results Level of serum IL-6 of the people in treatment group is obviously lower than that of control group. And the difference has statistical significance (P < 0.05).

Conclusions Yindan Xinnaotong Capsule has the function of restraining IL-6, stabilising coronary artery atherosclerosis plaque of UAP patients, preventing the occurrence of heart attack and having a certain protective effect on UAP.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.